ESH 4th International Conference on
HEMATOLOGIC MALIGNANCIES AT OLDER AGE:
BIOLOGY AND THERAPY
March 9-11, 2018 – Mandelieu, France
Chairs: Bob Löwenberg, Benjamin Ebert, Pierre Fenaux, Michael Hallek
The program of this conference will deal with the evolution of the hematopoietic system during aging, how this evolution contributes to the development of hematological malignancies, most of which predominate in the elderly as well as the diagnosis and therapeutic management of myeloid and lymphoid hematologic malignancies at older age.
For instance, the occurrence of somatic mutations in myeloid cells appear to be early steps in the pathophysiology of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), and epigenetic changes and bone marrow stroma modi cations occurring with aging may have a pathogenetic role in this development. Clonal B lymphocytosis and monoclonal gammopathies, mainly seen in the elderly, represent early phases of chronic lymphocytic leukemia (CLL) and myeloma, respectively. Aging of the immune system contributes to the higher rate of infections seen in elderly subjects.
The programme will explore potential intrinsic specific characteristics of haematological malignancies as they present in patients of older age, in comparison to younger patients, and discuss the therapeutic managemnent and specific requirements in older patients.
Special attention will be given to the utility and promise of new drugs, especially targeted drugs with reduced or no myelosuppression, that may be particularly useful in elderly patients.To analyze a frequent situation in the elderly, ie anemia.
Upon completion of this CME activity, participants should be able to:
Aging of the hematopoietic system and immune system
Early genetic events leading to the development of hematological malignancies, including AML, MDS, CLL, myeloma, and how they differ from the full blown diseases
Potential differences in disease characteristics in haematological malignancies in the elderly, as they may lead to different treatments compared to younger patients
How to assess the geriatric patients for comorbidities, functional aspects, particularly for treatment decisions
Treatments that can be used in hematological malignancies in the elderly, particularly those with no or limited myelosuppression, which may be particularly useful in patients of older age
Clonal hematopoiesis and aging
The aging hematopoietic system
Multiple myeloma, precursor lesions and management questions in the elderly
Lymphoma: clonal evolution and specific management strategies in the elderly
CLL and MBL, molecular evolution, and specific management strategies in the elderly
Lymphoma of high-risk phenotype: molecular characterization and optimal management